Triasima Portfolio Management inc. Acquires 30,971 Shares of Gilead Sciences, Inc. $GILD

Triasima Portfolio Management inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 838.2% in the second quarter, Holdings Channel reports. The fund owned 34,666 shares of the biopharmaceutical company’s stock after purchasing an additional 30,971 shares during the quarter. Triasima Portfolio Management inc.’s holdings in Gilead Sciences were worth $3,843,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in GILD. Brighton Jones LLC lifted its holdings in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $215,000. Miracle Mile Advisors LLC lifted its holdings in shares of Gilead Sciences by 21.4% in the 1st quarter. Miracle Mile Advisors LLC now owns 7,976 shares of the biopharmaceutical company’s stock valued at $894,000 after acquiring an additional 1,407 shares during the last quarter. CHICAGO TRUST Co NA bought a new position in shares of Gilead Sciences in the 1st quarter valued at about $258,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Gilead Sciences by 94.3% in the 1st quarter. Farther Finance Advisors LLC now owns 37,487 shares of the biopharmaceutical company’s stock valued at $4,172,000 after acquiring an additional 18,194 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $116.78 on Wednesday. The firm has a market cap of $144.90 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34. The firm’s 50 day simple moving average is $114.41 and its 200-day simple moving average is $110.06. Gilead Sciences, Inc. has a one year low of $84.17 and a one year high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director owned 8,920 shares in the company, valued at approximately $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on GILD. Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research report on Friday, August 8th. Rothschild & Co Redburn increased their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a research report on Friday, July 25th. Finally, UBS Group increased their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $117.17.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.